Table 3. Expression profiles of putative target mRNAs in miR-375.
| ID | AC vs. normal | SQ vs. normal | SCLC vs. normal | |||
|---|---|---|---|---|---|---|
| Corrected p-value | Fold change | Corrected p-value | Fold change | Corrected p-value | Fold change | |
| ACSL3 | 3.6E-02 | 0.2 | 3.6E-02 | 0.2 | 1.1E-02 | 10.5 |
| CACNG2 | 5.0E-03 | 0.2 | 3.3E-04 | 0.1 | 6.9E-01 | 1.2 |
| CCDC6 | 1.9E-03 | 0.2 | 1.2E-08 | 0.1 | 9.0E-01 | 0.9 |
| CSNK2A1 | 8.7E-02 | 0.7 | 2.5E-02 | 0.3 | 4.9E-01 | 1.4 |
| FZD8 | 4.4E-03 | 0.2 | 1.3E-07 | 0.03 | 2.4E-02 | 0.1 |
| ITGA10 | 6.0E-07 | 0.2 | 1.2E-12 | 0.01 | 9.1E-05 | 0.1 |
| ITPKB | 3.9E-04 | 0.1 | 1.2E-13 | 0.02 | 1.8E-04 | 0.04 |
| JAK2 | 8.0E-01 | 1.2 | 9.8E-01 | 1.0 | 6.8E-01 | 1.5 |
| JUND | 3.9E-04 | 0.1 | 1.2E-08 | 0.1 | 7.6E-01 | 0.8 |
| LAMC1 | 8.2E-01 | 1.2 | 2.0E-01 | 0.6 | 5.6E-01 | 1.6 |
| LRP5 | 2.5E-03 | 0.2 | 3.0E-10 | 0.03 | 5.1E-04 | 0.2 |
| MAP3K5 | 3.1E-01 | 0.6 | 3.0E-02 | 0.4 | 6.6E-01 | 1.3 |
| NLK | 8.5E-01 | 0.9 | 6.5E-01 | 0.8 | 3.2E-04 | 19.9 |
| PAK7 | ND | ND | ND | ND | ND | ND |
| PDGFC | ND | ND | ND | ND | ND | ND |
| PDPK1 | 6.3E-01 | 1.6 | 6.1E-01 | 0.6 | 4.0E-05 | 49.5 |
| PIAS1 | 9.4E-06 | 0.1 | 1.0E-13 | 0.01 | 8.0E-05 | 0.2 |
| RUNX1 | 10.0E-01 | 1.0 | 1.5E-11 | 0.1 | 2.0E-03 | 0.3 |
| RYR2 | 1.2E-02 | 0.2 | 7.0E-06 | 0.1 | 8.0E-01 | 1.2 |
| SOCS5 | ND | ND | ND | ND | ND | ND |
| SP1 | 4.1E-01 | 1.7 | 3.3E-01 | 1.7 | 3.4E-06 | 24.1 |
| WNT5A | ND | ND | ND | ND | ND | ND |
AC: adenocarcinoma, SQ: squamous carcinoma, SCLC: small celllungcarcinoma.
ND: not determined, the target gene did not pass the quality control process in which the target gene showed CT values above 35 cycles in > 20% of the tested samples.